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One of the challenges in environmental health is to attribute a certain health effect to a specific
environmental exposure and to establish a cause-effect relationship. Molecular epidemiology
offers a new approach to addressing these challenges. Mutations in the tumor suppressor gene
p53 can shed light on past environmental exposure, and carcinogenic agents and doses can be
distinguished on the basis of mutational spectra and frequency. Mutations in p53 have
successfully been used to establish links between dietary aflatoxin exposure and liver cancer,
exposure to ultraviolet light and skin cancer, smoking and cancers of the lung and bladder, and
vinyl chloride exposure and liver cancer. In lung cancer, carcinogens from tobacco smoke have
been shown to form adducts with DNA. The location of these adducts correlates with those
positions in the p53 gene that are mutated in lung cancer, confirming a direct etiologic link
between exposure and disease. Recent investigations have also explored the use of p53 as a
susceptibility marker for cancer. Furthermore, studies in genetic toxicology have taken advantage
of animals transgenic for p53 to screen for carcinogens in vivo. In this review, we summarize
recent developments in p53 biomarker research and illustrate applications to environmental
health. Environ Health Perspect 105(Suppl 1):155-163 (1997)
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Introduction
Because environmental exposures to chemi-
cal agents or radiation can occur at low
Ilevels over long periods oftime, it is often
difficult to determine associations between
exposure and disease, let alone prove causal-
ity. Therefore, investigations concerning
the health consequences ofenvironmental
exposure face a multitude ofchallenges.
First, the environmental fate ofxenobiotic
agents must be evaluated before they come
into contact with human populations.
Factors such as transformation, bioaccumu-
lation, and bioavailability in the environ-
ment will differentially affect the exposure
an individual receives (1) and the routes by
which an individual is exposed. In addition,
population heterogeneity and interactions
between biologicalvariables such as inherited
metabolic characteristics and synergistic
effects ofmultiple envirorunental exposures
mayplayan important role aswell.
Once the complex task ofestablishing
exposure levels has been addressed, health
risks resulting from such exposure can be
determined. Toxicological dose-response
relationships and threshold effects are
usually extrapolated from animal data.
Molecular epidemiology offers a new
approach to establish associations between
exposure and disease by using types and
frequencies of mutations as molecular
dosimeters (2-4).
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By combining environmental epidemi-
ology with modern molecular techniques,
molecular epidemiology attempts to find
answers to questions regarding exposure and
risk (5). For example, is the lung cancer of
a miner due to environmental radon expo-
sure or smoking? Do dietary carcinogens
play a role in the liver cancer ofa patient,
or is the disease a result of endogenous
processes? Molecular epidemiology offers a
new approach to risk assessment in cases
such as these.
The first interaction between xenobiotic
compounds and organisms occurs on a
molecular level prior to any clinical mani-
festation. Thus, if a target molecule of a
toxic agent is known, changes in that mole-
cule may be used as a biomarker and the
biological dose or effect ofan environmen-
tal exposure may be measured directly in
biological samples. The powerofmolecular
epidemiology in environmental exposure
assessment lies in the use ofsuch biomark-
ers, which attempt to infer exposure and
identifyexposure-related health risks.
When biomarkers are used to directly
measure the molecular impact ofexposure,
subclinical responses can be detected.
Therefore, biomarkers allow exposure to be
determined prior to any dinical manifesta-
tion ofhealth effects, allowing the mini-
mization ofadverse outcomes through the
prevention ofcontinued exposure.
The tumor suppressor gene (TSG) p53
is an ideal biomarker ofeffect for addressing
such questions ofexposure and risk. The
p53 gene is expressed in every cell ofthe
human body and the p53 protein has been
shown to playacrucial role in the regulation
ofcell division, making it a central molecule
in the life ofa cell (6). Inactivation ofthe
p53 gene can result in uncontrolled cell
division and ultimately lead to cancer (7).
Such inactivation frequently occurs as a
result ofmutations caused by exposure to
environmental mutagens (3,4). However,
inactivation ofp53 can also occur sporadi-
cally through endogenous processes, and in
rare cases, mutations in p53 can be inher-
ited. The ability to distinguish between dif-
ferent types ofmutations in p53 as well as
to link exposure to specific patterns and
types ofmutations in the gene makes p53
an ideal tool in molecularepidemiology.
p53and Cancer
Cancer is a complex process, a result ofthe
cell cycle gone awry. Tight control over
cellular proliferation is essential for the life
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ofan organism, in which growth is stimu-
lated by protooncogenes and counterbal-
anced by growth-inhibiting TSGs such as
p53. Mutations that activate protooncogenes
can turn them into oncogenes and result in
tumor growth. On the other hand, muta-
tions that inactivate TSGs release growth
inhibition, also leading to tumorigenesis (8).
While mutations in protooncogenes
result in a gain offunction and are therefore
dominant, overriding the presence ofthe
wild-type copy ofthe gene, recessive TSG
mutations result in loss offunction and a
single mutant copy will thus be masked by
the presence of the remaining wild-type
copy (8). Therefore, in most cases, both
copies ofa TSG must be mutated in order
to see an effect. In many instances, one
copy ofp53 is inactivated by a point muta-
tion while the other allele has been deleted
(7). The initiation ofcancer often results
when mutations in both protooncogenes
and TSGs occur simultaneously.
Thep53gene is one ofthe most promi-
nent members ofthe TSG family. Its pro-
tein product is a nuclear transcription
factor (7) that regulates the activity ofsev-
eral genes, induding that ofp2l, which is
directly involved in cell cycle control
(9-11). p21 exerts its effect by binding to
and inactivating cyclin-dependent kinases
(CDK), preventing the cell cycle from pro-
gressing (Figure 1). Mutated p53 as found
in human cancers is unable to activate the
p21 gene, leading to a release ofthe normal
cell cycle block and thus to uncontrolled
cellular growth (12).
Control of the cell cycle checkpoint
becomes increasingly important when a cell
has suffered from extensive DNA damage.
p53 plays a crucial role in preventing such
cells from multiplying by initiating pro-
grammed cell death (apoptosis) (13-15).
When p53 is mutated and can no longer
activate apoptosis, such damaged cells are
able to continue proliferating, potentially
resulting in cancer.
p53as a Biomarker
The usefulness ofp53 as a biomarker of
effect is 5-fold:
a) p53 is altered in tumors ofmore than
50% ofall cancer patients (16-18). This
finding reflects the central role played by
p53 in cell cycle control and cancer. This
high prevalence ofp53 mutations means
that the probability offinding mutations in
this gene in a given cancer patient popula-
tion is likely, allowing for the establish-
ment ofstatistically significant associations
between mutations and exposures.
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Figure 1. Transcriptional activation ofthe p21 gene by p53and cyclin-mediated cell cycle control.
b) Mutations in thep53 gene are found
in nearly all types of cancer studied (19).
Because mutations in p53 are widespread,
having been identified in such diverse types
of cancer as lung, breast, colon, esophagus,
lymphomas, and leukemias, (16) p53 is
a useful tool for assessing associations
between environmental exposure and a
multiplicity of types of cancer. Thus, p53
lends itself to the study ofthe carcinogenic
process in relation to carcinogens even in
the case ofrare tumor types.
c) Specific types of cancer are associated
with characteristic mutation patterns in
p53. Particular mutation patterns in p53
have been observed to correlate with
specific types of cancer (16). The so-called
mutational spectrum, the pattern ofloca-
tion and type ofmutations within the p53
gene, has been shown to differ between
cancers of the lung, colon, liver, breast,
brain, esophagus, reticuloendothelial tissue,
and hemopoetic tissues, allowing investiga-
tion of the etiology of the carcinogenic
process in different tissues.
d) Specific mutational spectra in p53
can be linked to specific exposures (18).
Most importantly for environmental
health, certain mutagens have been shown
to leave mutational fingerprints in the p53
gene-characteristic patterns ofmutations
that can be indicators ofspecific exposures.
On the basis ofthese fingerprints, endoge-
nous mutagenic events can often be distin-
guished from those resulting from exposure
to exogenous agents, thus shedding light
on the etiology and molecular pathogenesis
of cancer. Furthermore, it has been possible
to identify carcinogens on the basis ofsuch
mutational spectra and to determine the
dose by using the frequency ofmutations
as a molecular dosimeter (3,18).
e) The location ofadducts between car-
cinogens and DNA can be mapped along
the sequence ofp53 (20). Preferential loca-
tion ofsuch adducts at particular positions
in the p53 gene correlates with the sites of
mutational hot spots found in certain
cancer types. Thus, the p53 gene can be
used to identify direct causal links between
chemical exposures and disease.
p53and Exposure
Assessment
Because ofthe widespread involvement of
p53 in many types of cancer, significant
information concerning links between
specific exposures, mutations in p53, and
cancer type is available. The p53 gene has
been isolated and sequenced in a wide vari-
ety of cancers and the presence ofsignature
mutations in several exposure-induced types
of cancer has been described (Table 1).
These findings indicate that the p53 gene
can be used as an indicator to reconstruct
exposure and to identify the carcinogen
responsible for the mutation. Mutations
resulting from endogenous mechanisms are
thought to differ from exposure-induced
events. For example, more than two-thirds
ofthe mutations found in colon cancer are
transitions at CpG sites (16). It has been
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Table 1. Exposure to environmental agents, mutation in p53, and cancer outcome.
Exposure Cancertype Mutation in p53 Reference
Dietary aflatoxin Hepatocellular carcinoma G-T or G-+C transversions, (21-23)
(liver) particularly atcodon 249
UV irradiation Squamous and basal cell C->T substitutions at dipyrimidine sites (24-26)
carcinomas (skin)
Tobacco smoke Lung cancer G:C to T:Atransversions, (16,27-30)
particularly atcodons 157, 248, 273
Bladder cancer G:C to C:G transversions, higherdouble (31,32)
mutation frequency
Vinyl chloride Angiosarcoma (liver) A:TtoT:Atransversions, anti-p53 (33,34)
antibodies in sera
speculated that CpG sites are susceptible to
spontaneous methylation followed by
deamination and that the resulting muta-
tion is due to endogenous rather than
exogenous processes (3).
The usefulness ofp53 in exposure
assessment is illustrated in the following
sections.
Dietary Aflatoxin B1
One ofthe best documented examples of
the value ofp53 as a biomarker ofeffect is
the association that has been established
between exposure to dietary aflatoxin B1
(AFB1), hepatocellular carcinoma (HCC)
ofthe liver, and mutation in thep53 gene.
AFB1, a fungal mycotoxin produced by
Aspergillusflavus, is a common contami-
nant in grains, nuts, and oil seeds in cer-
tain geographical regions. In areas where
exposure is endemic, such as sub-Saharan
Africa and southern China, dietaryAFB1 is
considered a major risk factor for HCC
(35,36), which occurs at high levels in
the population. Hepatitis B infection is
often also common in these regions and
is considered to have a substantial and
perhaps synergistic causative role in the
development ofHCC (37,38).
Examination ofthe p53 gene in HCC
tumors from patients residing in Qidong,
China, an area ofboth high AFB1 exposure
and endemic Hepatitis B infection,
revealed a prevalence ofpoint mutations at
the third base position of codon 249.
Many of the point mutations observed
were G-*T or G-*C transversion events
(21). In contrast, nonmalignant liver tissue
from patients with p53 mutations in the
tumor showed no mutation in p53. Thus,
there is a striking correlation between the
presence ofp53 mutation and malignancy.
Studies ofHCC tumors from patients resid-
ing in sub-Saharan Africa, also a region of
both high AFB1 exposure and high rates of
hepatitis B virus (HBV) infection, revealed
strikingly similar patterns of mutation in
the p53 gene; many of the mutations
observed were G-+T transversions, with a
hot spot at codon 249 (22).
An association between dietary AFB1
exposure and G->T transversions in HCC
is supported by in vitro studies that have
demonstrated that metabolites ofAFB1 are
capable ofbinding to DNA and inducing
G-+T transversions (23). In studies of
DNA-repair deficient human cells, AFB1
metabolite exposure resulted in a high fre-
quency ofbase substitutions at G:C pairs
and transition mutations at GG sites.
Furthermore, experiments in which human
hepatocytes were exposed to AFB1 metabo-
lites in vitro revealed a high frequency of
G->T transversion events at codon 249, a
result consistent with observations in
tumors from populations in areas with
highAFB1 exposure (39).
Whereas these studies implicate AFBi
exposure in specific patterns ofmutation in
p53, HBV infection has also been estab-
lished as a risk factor for HCC and there-
fore is likely to also play a role in events
leading to carcinogenesis. However, a
study of HCC in Hong Kong, a high
prevalence area for HBV infection but a
low-exposure area for AFB1, showed a
lower frequency of mutation in p53 than
was observed in tumors from China and
sub-Saharan Africa, with no clustering of
mutations at codon 249 (40). In addition,
when tumors from Qidong, China, were
assessed for the presence ofHBV infection,
no correlation was found between the state
ofHBV DNA and mutations in p53 (41).
Experimental evidence suggests that HBV
infection is likely to contribute to HCC by
inhibiting the activity ofwild-type p53,
rather than through mutagenesis of the
p53gene. A protein encoded by HBV, pro-
tein X, has been shown to bind to the wild-
typep53gene product and inhibit its DNA
binding and transcriptional activity in vitro
(42). Thus, it is likely that HBV infection
increases the probability of developing
HCC as a result of a synergistic effect
with mutations in p53 stemming from
AFB1 exposure.
The specificity of the link between
G-4T transversion events, particularly at
codon 249, and AFB1 exposure is further
supported by studies of HCC cases from
regions where neither AFBI exposure nor
HBV infection is common. One of these
studies revealed a high frequency ofp53
overexpression in HCC tumor cells linked
to mutations in the p53 gene (43).
However, the codon 249 mutation that
was frequently observed in AFBI-exposed
populations was not a predominant muta-
tion event in these HCCs (43). Studies
with additional cases showed no consistent
pattern of mutation in p53 and the fre-
quency ofmutation at codon 249 was low
(44,45). Additional support for the causal-
ity ofAFB1 in the development ofHCC is
provided by the presence of mutations at
codon 249 in nonmalignant liver tissue
from HCC patients in areas with high
AFB1 exposure (46). These studies corrob-
orate the evidence linking exposure to
AFB1 with mutations at codon 249 ofthe
p53gene in cases ofHCC tumors.
Ultraviolet Irradiation
Exposure to ultraviolet (UV) irradiation
has been implicated in the etiology of
many types ofskin cancers (47). Because
UV exposure is often preventable by the
use ofsunscreens or the reduction of time
spent in the sun, public health implications
ofthe relationship between UV exposure
and skin cancer are ofgreat practical impor-
tance. Because UV exposure is well estab-
lished as the most consistent and significant
cause ofskin cancer in humans, the ability
to locate specific patterns of mutation in
p53 on the causal pathway between expo-
sure and disease provides an excellent
example of the power of biomarkers in
assessing environmental exposure.
Exposure to UV light has been shown
to increase the risk ofsquamous cell (SCC)
and basal cell (BCC) carcinomas, as well as
the risk ofmelanoma (47,48). At the mol-
ecular level, it has been demonstrated that
exposure to UV light leads to CC-4TT
double base substitutions and C-÷T
substitutions at dipyrimidine sites. Such
dipyrimidine mutations are a signature of
UV exposure; rarely do these types of
mutations result from exposure to other
mutagens (49,50).
In cases of skin cancer, particularly
SCC (24) and BCC (25,26), mutations in
p53 have been detected predominantly at
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dipyrimidine sites and are frequently C-4T
substitutions, suggesting a relationship
between UV exposure, p53, and carcino-
genesis. Further implicating an association
between UV exposure and the presence of
p53 mutations in these cases is the fact that
all ofthe tumors in which p53 mutations
were observed came from sun-exposed sites
on the body, whereas tumors occurring at
nonexposed sites on the body showed no
correlation with mutations inp53 (25,51).
When normal skin cells were subjected to
varying degrees ofUV irradiation in vitro
and assessed for CC->TT transitions at
codons 245 and 247/248 ofp53, such
mutations were observed to occur accord-
ing to a dose-response relationship. The
presence ofpyrimidine dimer mutations at
certain hot spots in thep53gene is thought
to be a result of slow repair ofdimers at
specific sites (52).
Smoking
Tobacco smoking has been associated with
an elevated risk for multiple types of
human cancers (53,54). Moreover, several
of the approximately 3800 chemicals
identified in tobacco smoke have been
shown to cause cancer in laboratory ani-
mals (55). Two components of tobacco
smoke, benzo[a]pyrene (B[a]P), a poly-
cyclic aromatic hydrocarbon (PAH), and
4-aminobiphenyl, an arylamine, form
adducts with DNA, suggesting that these
components may be direct mutagens.
DNA adducts containing B[a]P have been
found in lung tumors from smokers
(56-59) and 4-aminobiphenyl has been
identified in DNA adducts in bladder
tumors from smokers (60). The presence
of tobacco smoke components in DNA
adducts from smoking-associated tumors
strongly suggests that direct DNA mutage-
nesis plays a role in the increased cancer
risk associated with tobacco smoking.
Several studies have determined that
G:C to T:A transversions are the most
commonly observed mutation events fol-
lowing experimental exposure to polycyclic
aromatic hydrocarbons such as B[a]P
(27-30,61), and other components of
tobacco smoke have been shown to lead to
G:C to TA transversions aswell (16,62).
Studies investigating p53 mutations in
lung cancers have shown that G:C to T:A
transversions on the nontranscribed strand
of the p53 gene occur at a significantly
higher frequency in lung cancers than in
other types ofcancer (4,63,64), suggesting
an association between exposure to tobacco
smoke components, such as PAHs, and
these mutations. Conversely, the frequency
of transition mutations at CpG residues,
presumed to arise from endogenous causes,
is also significantly lower overall in lung
cancer than in most other types ofcancer.
This would suggest a stronger than usual
role ofdirect mutagenesis in lung cancers
as compared to other types of cancer.
However, among the small subgroup of
lung cancers occurring in nonsmokers
(tobacco smoking is thought to account for
up to 90% ofall pulmonary malignancies),
the pattern is reversed. Fewer incidences of
G:C to T:A transversion events inp53have
been observed; most ofthe p53 mutations
in these cancers are G:C to A:T transition
mutations (65,66). Thus, the specific and
distinctive mutation pattern ofG:C to T:A
transversion events in the p53 gene pre-
dominates in cases oflung cancer associ-
ated with smoking, whereas lung cancer
cases not associated with smoking tend to
display the more widespread and endoge-
nous G:C to A:T transition mutations.
Therefore, the presence of G:C to T:A
transversions in the p53 gene, particularly
on the nontranscribed strand, serves as a
specific biomarker of effect of tobacco
smoke and is likely to be induced by one or
more components found in tobacco smoke.
Further supporting the association
between such mutations in p53, lung
cancer, and smoking are the results ofsev-
eral studies (64-66). These studies show
that in lung cancers not only is there a
direct association between smoking and the
frequency ofmutation or state ofthe p53
protein, but the relative frequency ofsuch
events correlates with lifetime cigarette con-
sumption. Additionally, several hot spots at
guanine residues have been identified in
lung cancers at codons 157, 248, and 273,
which lie within the DNA binding domain
ofp53 (20). Ofthese, the mutational hot
spot at codon 157 is specific for lung cancer
and has not been identified as a hot spot in
other cancer types.
Recently, a direct etiologic link between
tobacco smoke and lung cancer has been
established in a study examining B[a]P
adduct formation in the p53 gene (Figure
2). When bronchial epithelial cells were
exposed to benzo[a]pyrene diol epoxide,
the metabolically active form of B[a]P,
strong and selective adduct formation was
observed at codons 157, 248, and 273 (20).
Since these codons are identical to those
mutated in lung cancer, this finding for-
mally establishes the link between exposure
and disease in tobacco smoke exposure.
Tobacco smoking has also been associ-
ated with increased risk for bladder cancer
(67-72). Mutations inp53were one ofthe
first genetic alterations to be associated
Normal cell
p p53
DNAadductformation
Exposure:tobacco smoke
;Cancercells
Disease: lung cancer
Figure 2. Causal link between exposure and disease: tobacco smoke and lung cancer.
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with primary invasive bladder cancers (73).
In immunohistocytochemical studies of
patients with early stage bladder cancer, a
significant association between the number
of cigarettes smoked per day and the fre-
quency of nuclear staining for p53 was
observed (74). Studies comparing cases of
bladder cancer from smoking and non-
smoking patients showed that an increased
frequency of G:C to C:G transversion
events in the p53 gene was associated with
both groups (31,32). Although no differ-
ence in the spectrum ofmutation types was
found, smokers were observed to have a
higher frequency ofdouble mutation events
in the p53 gene. One study ofJapanese
patients with a variety ofurothelial cancers,
including bladder cancer, showed that
although the frequency ofp53 mutation
did not substantially differ between smok-
ers and nonsmokers, tumors from smokers
exhibitedA:T to G:C transitions in thep53
gene at a significantly higher frequency
than tumors from nonsmokers (31).
Vinyl Chloride
Occupational exposure to vinyl chloride
during the manufacture ofplastics has been
tied to the occurrence ofangiosarcoma of
the liver (ASL), a rare form of cancer
(75,76). Most exposure to vinyl chloride
occurred between 1950 and 1980, prior to
the discovery of its carcinogenic effect.
Because such exposure has been remark-
ably well documented, studies ofworkers
exposed to vinyl chloride provide an excel-
lent opportunity for establishing associa-
tions between environmental exposure,
mutation spectra, andASL.
Serum from workers exposed to vinyl
chloride tested positive for anti-p53 anti-
bodies; many ofthose who tested positive
either had ASL at the time of testing or
went on to develop ASL at a later date
(33). In contrast, serum from lung cancer
patients tested positive at a significantly
lower frequency, whereas serum taken from
individuals with neither vinyl chloride
exposure nor cancer showed no reactivity
at all (33). Thus, the presence ofanti-p53
antibodies in serum from workers exposed
to vinyl chloride may be a useful indicator
for risk or presence ofASL.
When ASL tumors from workers
exposed to vinyl chloride were analyzed for
mutations in p53, a significant frequency
ofA:T to T:Atransversions, an uncommon
mutation event in the majority ofhuman
types ofcancer, was observed (34). Tumor
tissues from those vinyl chloride-exposed
workers who tested positive for anti-p53
antibodies also showed these unusual A:T
to T:A transition events in p53 (33).
Usually, mutations in p53 are rare events
in sporadic ASL (77) and when they do
occur, they are usually G:C to A:T transi-
tions consistent with endogenous mecha-
nisms. However, A:T to T:A transversions
are characteristic ofchloroethylene oxide, a
carcinogenic metabolite ofvinyl chlorides
(76). Therefore, such mutations can be
used as biomarkers ofeffect resulting from
exposure to vinyl chloride.
p53as a Susceptibility Marker
Mutations
p53 mutations can be inherited as well as
acquired. Individuals with the rare Li-
Fraumeni syndrome are at increased risk of
acquiring breast carcinomas, soft tissue sar-
comas, brain tumors, osteosarcomas,
leukemia, and adrenocortical carcinomas
(78). This syndrome results from germline
mutations inp53 (79).
Although individuals carrying germline
mutations in p53 can usually be identified
on the basis of a family history ofcancer
(i.e., Li-Fraumeni syndrome), the identi-
fication ofindividuals at riskwho lack such
a family history poses technical problems
for traditional techniques. In the absence
of a family history of cancer, a molecular
assay developed in yeast can be used to
screen for individuals with germline muta-
tions (80). This functional assay distin-
guishes between mutations that affect the
function ofthe protein (and are therefore
likely to lead to increased susceptibility to
cancer) and polymorphisms not likely to
alterwild-typep53function.
Polorphisms
Polymorphisms differ from mutations in
that they occur at a higher frequency in the
population (>1%) and do not necessarily
affect the function ofthe protein. In many
cases, polymorphisms do not alter the
amino acid sequence, although they some-
times alter the expression of the gene.
Therefore, polymorphisms inp53cannot be
identified by the functional yeast assay
because they do not affect protein function
(although they can still result in a predispo-
sition for certain cancers). To date, several
polymorphisms inp53 have been described,
two ofwhich have been implicated in cancer
susceptibility and are described below.
Codon72 (Pro) Polymorphism
The wild-type form of the p53 protein
occurs in two variants at codon 72, arginine
(Arg) and proline (Pro), which appear to
be functionally equivalent. An initial study
investigating smoking-associated lung
cancer in Japan identified a possible associ-
ation between the homozygous Pro/Pro
polymorphism at codon 72 of the p53
gene and cancer risk (81). Additional
studies found a similarly increased fre-
quency of the Pro/Pro polymorphism at
codon 72 in smoking-related cancers,
although the statistical significance ofthese
results was borderline (82,83). The impor-
tance ofpolymorphisms in codon 72 as a
marker for cancer susceptibility remains to
be determined.
Polymorphism inIntron3
A recent study with a Swedish population
oflung cancer patients determined that the
Pro/Pro polymorphism at codon 72 itself
showed no association with cancer; in com-
bination with the lack ofa 16 bp duplica-
tion in intron 3 ofthe p53 gene, however,
the Pro/Pro polymorphism was associated
with risk for lung cancer (84). The same
disequilibrium between the Pro/Pro poly-
morphism at codon 72 and the lack ofthe
16 bp duplication has been associated with
increased risk for colorectal cancer (85).
Conversely, the presence ofthe same 16 bp
duplication in intron 3 has recently been
associated with sporadic ovarian cancer in a
population of Caucasian Germans (86).
However, an increased allele frequency for
the 16 bp insertion was not detected in an
American population of ovarian cancer
patients, possibly as a result ofgeographic
differences and allele frequencies (87).
Because there is no consistent causal rela-
tionship between either the absence or the
presence ofthe 16 bp insertion in intron 3
and cancer, both this polymorphism and
the Pro/Pro polymorphism at codon 72 in
the p53 gene are probably linkage markers
for an as-yet unidentified region that
confers susceptibility to cancer (84).
The use of susceptibility markers to
identify individuals with an inherited pre-
disposition to cancer can improve the
efficiency of cancer screening and cancer
prevention efforts. A simple blood test has
been used to identify the 16 bp insertion
polymorphism in patient serum and could
be applied to circumvent the traditionally
difficult diagnosis ofearly ovarian cancer
by identifying individuals at risk. Ifcancer-
prone individuals can be identified by the
use ofsusceptibility markers, they can be
assisted in minimizing environmental
exposures (i.e., tobacco smoke) that put
them at increased risk.
Environmental Health Perspectives * Vol 105, Supplement * February 1997 159SEMENZAAND WEASEL
p53in GeneticToxicology
Cancerogenesis is thought to be a multistage
process involving initiation, promotion,
and progression. Understanding how
carcinogens function requires the elucida-
tion ofthe roles they play in each ofthese
stages ofcancer development. Because p53
is a central molecule in cell cycle regulation
and growth control, its interaction with
various carcinogens can shed light on the
ways in which they contribute to the
cancerous state.
The development oftransgenic animals
possessing null alleles ofp53provides an in
vivo model for analysis ofcarcinogen func-
tion. Although animals homozygous for
null alleles ofp53 have been shown to be
developmentally normal, they have shown
an increased susceptibility to spontaneous
tumors, thus making them inappropriate
for toxicological studies (88). However,
animals heterozygous for null alleles ofp53
have a reduced rate ofspontaneous tumors
relative to homozygotes; these animals have
proven to be useful tools for studying the
carcinogenic process and for identifying
carcinogens and teratogens.
Transgenic mice possessing one copy of
a null allele ofp53 have proven to be valu-
able for rapid and sensitive assessment of
the effects ofxenobiotic exposures in rela-
tion to the timing of tumorigenesis. A
recent study ofskin cancer in such animals
found that in one instance ofchemically
induced tumorigenesis, p53was involved in
malignant progression but not in initiation
or promotion (89).
Heterozygous null p53 animals can
also be useful in identifying chemicals that
are potential environmental carcinogens.
Exposure of these animals to dimethyl-
nitrosamine (DMN), a potent liver car-
cinogen, showed a higher frequency of
spontaneous tumors than in exposed wild-
type animals, providing a sensitive assay
with which to assess the effects ofcarcino-
gens (90). Furthermore, in heterozygous
null animals, the mutational spectra for
specific chemicals can be evaluated for dif-
ferent types of cancer and compared with
human data. Certain mutant forms ofp53
can be reintroduced into heterozygous null
and homozygous null mice in order to
study the selective predisposition of cer-
tain mutant forms ofp53 to specific tumor
type (91,92). Such mice can also aid
in the determination of signature muta-
tions in p53 in cases ofradiation-induced
tumors, since p53-deficient mice are
highly susceptible to even minor doses of
radiation (93,94).
Transgenic mice deficient forp53 have
also been used to screen for environmental
teratogens and have been found to be a
sensitive tool with which to study embry-
onic development. In one such study, the
embryotoxicity and teratogenicity of
benzo[a]pyrene was found to be 2- to
4-fold higher in p53-deficient mice than
in wild-type controls (95). In utero death
was 2.6- and 3.6-fold higher, respectively,
in heterozygous and homozygous p53-
deficient embryos.
However, neither standardized lifetime
bioassays in wild-type rodents exposed to
daily, near-toxic doses, nor short-term tests
to assess the mutagenicity ofchemicals in
wild-type animals, have resulted in p53
mutational spectra comparable to that seen
in human cancers. Thus, p53 seems not
to play the same central role in animal
tumorigenesis as it does in human tumori-
genesis (96). These newly developed p53-
deficient mice will aid genetic toxicology in
identifing natural and synthetic com-
pounds that pose potential risk to human
health (97). In controlled animal experi-
ments, the effect ofa certain chemical on
p53 can be evaluated and compared with
results from exposed human populations.
MethodsforIdentifying
Mutations inp53
Because specific types or patterns of
mutation in thep53 gene can serve as indi-
cators or predictors of cancers resulting
from exposure, the detection ofsuch muta-
tions is important not only for establishing
a cause-effect relationship between expo-
sure and disease, but also for screening of
exposed populations prior to the onset of
cancer. Therefore, accurate, timely, and
cost-efficient methods ofidentifying such
mutations are needed. Three general diag-
nostic approaches to the detection ofp53
mutations can currently be used to screen
for mutations inp53.
The first and most direct approach is to
evaluate thep53gene sequence from tumor
tissue and analyze it for mutations. How-
ever, since this is often a time-consuming
and cosdy procedure, especially when con-
ducted on awidespread basis, other prelim-
inary screening approaches are often used
to detect cases in which p53 mutation is
likely. The most common of these is
immunohistochemistry, a method that relies
on the increased half-life ofmany mutant
p53 proteins. Because oftheir longer half-
life, mutant p53 proteins can be detected
in cells, whereas wild-type p53 eludes
detection because ofits short half-life (98).
Recent studies also indicate that antibodies
to p53 are present in the serum ofindivid-
uals with p53 mutations. This can be
applied as a screening method; studies of
both breast and lung cancer have shown
elevated levels ofanti-p53 antibodies in the
serum of individuals with mutations in
p53 (99,100).
Analysis ofthe p53 protein is not always
a good indicator of mutations in the p53
gene, since the protein can be inactivated,
for example by interactions with viral pro-
teins. Furthermore, analysis ofthe protein
by immunohistochemistry cannot deter-
mine the type and location ofmutations in
p53, which is essential information when
the p53 gene is used as a biomarker of
exposure or dose. Therefore, even when
analysis of the p53 protein suggests that a
mutation may be present, it is still necessary
to screen for mutations at the gene level.
There are several ways that the p53
gene can be analyzed at the genetic level
and screened for mutations in its sequence.
If the site of the mutation is not known,
prescreening with denaturing gradient gel
electrophoresis or single-strand conforma-
tion polymorphism can be used (101,102).
Either of these two methods will allow
rapid screening of mutations without
labor-intensive sequencing of the entire
gene. When the location ofthe mutation
has been narrowed to a particular exon,
polymerase chain reaction in combination
with restriction fragment length polymor-
phism can effectively identify the specific
nature ofindividual mutations (103,104).
Ifno restriction site is associated with the
mutation in question, then direct sequenc-
ing must be used to determine the nature
ofthe mutation.
Limitations
Population-based studies are needed to
evaluate critical epidemiologic features of
p53, such as the predictive value positive,
sensitivity, and specificity. Studies pre-
sented in this review are predominantly
case reports and thus the prevalence of
p53 mutations in the general population
cannot be estimated. Therefore, it is
difficult to estimate how predictive a cer-
tain mutation is for a specific exposure
with the data available in the current liter-
ature. It would be desirable to usep53 as a
biomarker of effect in different epidemio-
logic study designs such as cohort and case
control. Rigorous epidemiologic evalua-
tion of such data would be required to
translate and implement these findings in
public health practice.
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Furthermore, there are substantial
ethical considerations which must be taken
into account concerning the use ofp53as a
biomarker in public health. The use of
such biomarkers is susceptible to consider-
able abuse, i.e. cancellation of insurance
policies and violation ofequal opportunity
laws. Therefore, the practical implication
ofp53 as a biomarker may be limited due
to social restraints.
Conclusions
In this briefreview we have restricted our
discussion to p53 research as it pertains to
environmental health. Because oftheprimary
rolep53plays in the life ofa cell, induding
its involvement in apoptosis, DNA repair,
and cell proliferation and division, a vast
bodyofknowledge exists regarding its func-
tion (6). This knowledge can be applied to
the development ofeffective environmental
health tools for usingp53as a biomarker of
effect. Several examples ofmutational spec-
tra associated with specific exposures and
doses have already been elucidated; further
research is likely to extend the range ofenvi-
ronmental exposures that can be associated
with disease through the use ofp53.
In particular, p53 shows promise for the
assessment ofcancer susceptibility as well as
for in vivo identification of carcinogens.
More work is needed to identify specific
markers for susceptibility, and the develop-
ment ofanimals transgenic forp53 is likely
to facilitate an understanding ofhow car-
cinogens act on p53 and lead to cancer.
The use ofbiomarkers, particularly genes
such as p53, is a rapidly expanding field in
environmental health and has vast potential
for increasing our knowledge and aware-
ness ofthe impact of the environment on
human health.
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